Delving into the Latest Updates on Kindai University Faculty of Medicine with Synapse

Overview

Tags

Nervous System Diseases

Respiratory Diseases

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

TBXA2R(Thromboxane A2 receptor)	1
EGFR C797S x EGFR T790M	1

A 54-year-old woman diagnosed with eosinophilic granulomatosis accompanied by polyangiitis (EGPA) was in remission with prednisolone (PSL) and mepolizumab treatment. During the disease course, vasculitis recurrence was not apparent, but her asthma became uncontrollable and was accompanied by elevated antineutrophil cytoplasmic antibody (ANCA) levels. Asthma control did not improve after switching from mepolizumab to another biological agent, benralizumab. Consequently, the treatment with benralizumab was changed to tezepelumab, after which her symptoms immediately improved and her ANCA levels decreased, enabling reduction in the PSL dosage. This case highlights the potential of tezepelumab to reduce ANCA levels in EGPA-related severe asthma.

100 Deals associated with Kindai University Faculty of Medicine

Login to view more data

100 Translational Medicine associated with Kindai University Faculty of Medicine

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Login to view more data